<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965818</url>
  </required_header>
  <id_info>
    <org_study_id>TAS-120-204</org_study_id>
    <nct_id>NCT04965818</nct_id>
  </id_info>
  <brief_title>Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer</brief_title>
  <official_title>A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib in Patients With Advanced KRAS Mutant Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib&#xD;
      in patients with advanced KRASmt tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, nonrandomized, uncontrolled Phase 1b/2 study to determine the&#xD;
      recommended phase 2 dose (RP2D) of futibatinib in combination with binimetinib and to explore&#xD;
      the preliminary antitumor activity of futibatinib in combination with binimetinib in patients&#xD;
      with advanced KRASmt tumors.&#xD;
&#xD;
      The study will consist of two parts:&#xD;
&#xD;
        -  Part 1: Dose-Escalation part to determine the RP2D of futibatinib in combination with&#xD;
           binimetinib in patients with advanced cancer disease&#xD;
&#xD;
        -  Part 2: Dose-Expansion part to evaluate the preliminary antitumor activity of&#xD;
           futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt&#xD;
           NSCLC&#xD;
&#xD;
      Patients will receive study treatment until progressive disease or any other discontinuation&#xD;
      or withdrawal criterion is met.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) in Part 1</measure>
    <time_frame>12 months</time_frame>
    <description>Determine RP2D of futibatinib in combination with binimetinib based on Dose Limiting Toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) in Part 2</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>proportion of patients who have achieved a PR or complete response (CR) according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of futibatinib, binimetinib, and AR00426032</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Plasma concentrations of futibatinib, binimetinib, and AR00426032</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area under the plasma concentration-time curve (AUC) of futibatinib, binimetinib, and AR00426032</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Plasma concentrations of futibatinib, binimetinib, and AR00426032</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to reach maximum plasma concentration (Tmax) of futibatinib, binimetinib, and AR00426032</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Plasma concentrations of futibatinib, binimetinib, and AR00426032</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Terminal elimination half-life (T1/2) of futibatinib, binimetinib, and AR00426032</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Plasma concentrations of futibatinib, binimetinib, and AR00426032</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Minimum plasma concentration before administration (Cmin) of futibatinib, binimetinib, and AR00426032</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Plasma concentrations of futibatinib, binimetinib, and AR00426032</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Accumulation ratio of Cmax and AUC (R) of futibatinib, binimetinib, and AR00426032</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Plasma concentrations of futibatinib, binimetinib, and AR00426032</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>DOR is defined as the length of time between first response and the date of objectively documented progression of disease or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>PFS is defined as the time from date of first dose to objectively documented progression of disease or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) at 24 months</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>DCR is defined as the percentage of patients who have achieved a CR, PR, or SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-emergent adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Evaluate safety and tolerability of futibatinib in combination with binimetinib based on treatment-emergent adverse events per CTCAE v5.0(including serious adverse events),clinical laboratory parameters, ECGs, and vital signs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>KRAS Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Futibitanib in combination with binimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease.&#xD;
Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Futibatinib and Binimetinib</intervention_name>
    <description>Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle</description>
    <arm_group_label>Futibitanib in combination with binimetinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed advanced cancer of any tumor type (Part 1) or NSCLC with a&#xD;
             confirmed KRAS mutation as determined by local results (Part 2)&#xD;
&#xD;
          -  Appropriate candidate for experimental therapy&#xD;
&#xD;
          -  For patients in Part 2 only: Patient has radiographically measurable disease per&#xD;
             RECIST 1.1 criteria.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Adequate cardiac function (Left ventricular ejection fraction (LVEF) â‰¥50% )&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Must have tumor tissue specimen available (optional for patients in Part 1)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current evidence of calcium and phosphate hemostasis disorder or systemic&#xD;
             mineral imbalance with ectopic calcification of soft tissues&#xD;
&#xD;
          -  Current evidence of clinically significant corneal or retinal disorder as confirmed by&#xD;
             ophthalmologic examination.&#xD;
&#xD;
          -  Known untreated central nervous system (CNS) metastases or history of uncontrolled&#xD;
             seizures.&#xD;
&#xD;
          -  Significant gastrointestinal disorder(s) that could interfere with absorption of&#xD;
             futibatinib/binimetinib&#xD;
&#xD;
          -  Patients who have neuromuscular disorders that are associated with elevated creatinine&#xD;
             kinase (CK)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nital Soni</last_name>
    <phone>609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles UCLA Cancer</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lim</last_name>
      <phone>310-633-8400</phone>
      <email>ChristopherLim@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Lee Rosen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center North</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Stoner</last_name>
      <phone>317-621-3836</phone>
      <email>cstoner@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Bert O'Neil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon Ahnert, MD, PhD</last_name>
      <phone>713-563-1930</phone>
    </contact>
    <investigator>
      <last_name>Jordi Rodon Ahnert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Futibatinib</keyword>
  <keyword>Binimetinib</keyword>
  <keyword>MEKi</keyword>
  <keyword>FGFR</keyword>
  <keyword>FGFRi</keyword>
  <keyword>TAS-120</keyword>
  <keyword>KRASmt</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Futibatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

